Indaptus Therapeutics, Inc. (NASDAQ:INDP) Sees Significant Increase in Short Interest

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the recipient of a large growth in short interest in November. As of November 30th, there was short interest totalling 92,000 shares, a growth of 8.2% from the November 15th total of 85,000 shares. Currently, 1.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 111,200 shares, the short-interest ratio is presently 0.8 days.

Indaptus Therapeutics Stock Performance

Shares of NASDAQ:INDP opened at $0.95 on Tuesday. The stock has a market capitalization of $9.69 million, a price-to-earnings ratio of -0.56 and a beta of 1.46. The company has a 50 day moving average price of $1.18 and a 200 day moving average price of $1.63. Indaptus Therapeutics has a 1-year low of $0.84 and a 1-year high of $3.10.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.15. On average, sell-side analysts expect that Indaptus Therapeutics will post -1.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Maxim Group decreased their price objective on shares of Indaptus Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 target price on shares of Indaptus Therapeutics in a report on Wednesday, October 16th.

Indaptus Therapeutics Company Profile

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.